Establishment of a UK-wide network to facilitate the acquisition of quality assured FDG-PET data for clinical trials in lymphoma

S. F. Barrington; J. E. MacKewn; P. Schleyer; P. K. Marsden; N. G. Mikhaeel; W. Qian; P. Mouncey; P. Patrick; B. Popova; P. Johnson; J. Radford; M. J. O'Doherty

doi:10.1093/annonc/mdq428

Establishment of a UK-wide network to facilitate the acquisition of quality assured FDG-PET data for clinical trials in lymphoma

S. F. Barrington, J. E. MacKewn, P. Schleyer, P. K. Marsden, N. G. Mikhaeel, W. Qian, P. Mouncey, P. Patrick, B. Popova, P. Johnson, J. Radford, M. J. O'Doherty

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Multicentre trials are required to determine how [fluorine-18]-2-fluoro-2-deoxy-D-glucose-positron emission tomography imaging can guide cancer treatment. Consistency in quality control (QC), scan acquisition and reporting is mandatory for high-quality results, which are comparable across sites. Methods: A national positron emission tomography (PET) clinical trials network (CTN) has been set up with a 'core laboratory' to coordinate QC and interpret scans. The CTN is involved in trials in Hodgkin's lymphoma [Randomised Phase III trial to determine the role of FDG-PET Imaging in Clinical Stages IA/IIA Hodgkin's Disease (RAPID) and Randomised Phase III trial to assess response adapted therapy using FDG-PET imaging in patients with newly diagnosed, advanced Hodgkin lymphoma (RATHL)] and diffuse large B-cell lymphoma [Blinded evaluation of prognostic value of FDG-PET after 2 cycles of chemotherapy in diffuse large B-cell Non-Hodgkins Lymphoma, a sub-study of the R-CHOP-21 vs R-CHOP-14 trial (R-CHOP PET substudy)]. Approval to join requires scanner validation and agreement to follow a standard QC protocol. Scans are transferred to the core laboratory and reported centrally according to predetermined criteria. Results: The qualification procedure was carried out on 15 scanners. All scanners were able to demonstrate the necessary quantitative accuracy, and following modification of image reconstruction where necessary, scanners demonstrated comparable recovery coefficients (RCs) indicating similar performance. The average RC (±1 standard deviation) was 0.56 ± 0.095 for the 13-mm sphere. Reports from 444 of 473 (94%) patients in RAPID and 67 of 73 (92%) patients in RATHL were available for randomisation of therapy. Conclusions: The CTN has enabled consistent quality assured PET results to be obtained from multiple centres in time for clinical decision making. The results of trials will be significantly strengthened by this system. © The Author 2010. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.

Original language	English
Pages (from-to)	739-745
Number of pages	6
Journal	Annals of Oncology
Volume	22
Issue number	3
DOIs	https://doi.org/10.1093/annonc/mdq428
Publication status	Published - Mar 2011

Keywords

Clinical trial
Core laboratory
Hodgkin's lymphoma
Non-Hodgkin's lymphoma
Positron emission tomography
Quality control/quality assurance

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/annonc/mdq428

Cite this

Barrington, S. F., MacKewn, J. E., Schleyer, P., Marsden, P. K., Mikhaeel, N. G., Qian, W., Mouncey, P., Patrick, P., Popova, B., Johnson, P., Radford, J., & O'Doherty, M. J. (2011). Establishment of a UK-wide network to facilitate the acquisition of quality assured FDG-PET data for clinical trials in lymphoma. Annals of Oncology, 22(3), 739-745. https://doi.org/10.1093/annonc/mdq428

@article{bf1d6ea93f504604a82b11380981ba3c,

title = "Establishment of a UK-wide network to facilitate the acquisition of quality assured FDG-PET data for clinical trials in lymphoma",

abstract = "Background: Multicentre trials are required to determine how [fluorine-18]-2-fluoro-2-deoxy-D-glucose-positron emission tomography imaging can guide cancer treatment. Consistency in quality control (QC), scan acquisition and reporting is mandatory for high-quality results, which are comparable across sites. Methods: A national positron emission tomography (PET) clinical trials network (CTN) has been set up with a 'core laboratory' to coordinate QC and interpret scans. The CTN is involved in trials in Hodgkin's lymphoma [Randomised Phase III trial to determine the role of FDG-PET Imaging in Clinical Stages IA/IIA Hodgkin's Disease (RAPID) and Randomised Phase III trial to assess response adapted therapy using FDG-PET imaging in patients with newly diagnosed, advanced Hodgkin lymphoma (RATHL)] and diffuse large B-cell lymphoma [Blinded evaluation of prognostic value of FDG-PET after 2 cycles of chemotherapy in diffuse large B-cell Non-Hodgkins Lymphoma, a sub-study of the R-CHOP-21 vs R-CHOP-14 trial (R-CHOP PET substudy)]. Approval to join requires scanner validation and agreement to follow a standard QC protocol. Scans are transferred to the core laboratory and reported centrally according to predetermined criteria. Results: The qualification procedure was carried out on 15 scanners. All scanners were able to demonstrate the necessary quantitative accuracy, and following modification of image reconstruction where necessary, scanners demonstrated comparable recovery coefficients (RCs) indicating similar performance. The average RC (±1 standard deviation) was 0.56 ± 0.095 for the 13-mm sphere. Reports from 444 of 473 (94%) patients in RAPID and 67 of 73 (92%) patients in RATHL were available for randomisation of therapy. Conclusions: The CTN has enabled consistent quality assured PET results to be obtained from multiple centres in time for clinical decision making. The results of trials will be significantly strengthened by this system. {\textcopyright} The Author 2010. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.",

keywords = "Clinical trial, Core laboratory, Hodgkin's lymphoma, Non-Hodgkin's lymphoma, Positron emission tomography, Quality control/quality assurance",

author = "Barrington, {S. F.} and MacKewn, {J. E.} and P. Schleyer and Marsden, {P. K.} and Mikhaeel, {N. G.} and W. Qian and P. Mouncey and P. Patrick and B. Popova and P. Johnson and J. Radford and O'Doherty, {M. J.}",

note = "CRUK/07/033, Cancer Research UK, United Kingdom, Department of Health, United Kingdom",

year = "2011",

month = mar,

doi = "10.1093/annonc/mdq428",

language = "English",

volume = "22",

pages = "739--745",

journal = "Annals of Oncology",

issn = "1569-8041",

publisher = "Oxford University Press",

number = "3",

}

Barrington, SF, MacKewn, JE, Schleyer, P, Marsden, PK, Mikhaeel, NG, Qian, W, Mouncey, P, Patrick, P, Popova, B, Johnson, P, Radford, J & O'Doherty, MJ 2011, 'Establishment of a UK-wide network to facilitate the acquisition of quality assured FDG-PET data for clinical trials in lymphoma', Annals of Oncology, vol. 22, no. 3, pp. 739-745. https://doi.org/10.1093/annonc/mdq428

TY - JOUR

T1 - Establishment of a UK-wide network to facilitate the acquisition of quality assured FDG-PET data for clinical trials in lymphoma

AU - Barrington, S. F.

AU - MacKewn, J. E.

AU - Schleyer, P.

AU - Marsden, P. K.

AU - Mikhaeel, N. G.

AU - Qian, W.

AU - Mouncey, P.

AU - Patrick, P.

AU - Popova, B.

AU - Johnson, P.

AU - Radford, J.

AU - O'Doherty, M. J.

N1 - CRUK/07/033, Cancer Research UK, United Kingdom, Department of Health, United Kingdom

PY - 2011/3

Y1 - 2011/3

N2 - Background: Multicentre trials are required to determine how [fluorine-18]-2-fluoro-2-deoxy-D-glucose-positron emission tomography imaging can guide cancer treatment. Consistency in quality control (QC), scan acquisition and reporting is mandatory for high-quality results, which are comparable across sites. Methods: A national positron emission tomography (PET) clinical trials network (CTN) has been set up with a 'core laboratory' to coordinate QC and interpret scans. The CTN is involved in trials in Hodgkin's lymphoma [Randomised Phase III trial to determine the role of FDG-PET Imaging in Clinical Stages IA/IIA Hodgkin's Disease (RAPID) and Randomised Phase III trial to assess response adapted therapy using FDG-PET imaging in patients with newly diagnosed, advanced Hodgkin lymphoma (RATHL)] and diffuse large B-cell lymphoma [Blinded evaluation of prognostic value of FDG-PET after 2 cycles of chemotherapy in diffuse large B-cell Non-Hodgkins Lymphoma, a sub-study of the R-CHOP-21 vs R-CHOP-14 trial (R-CHOP PET substudy)]. Approval to join requires scanner validation and agreement to follow a standard QC protocol. Scans are transferred to the core laboratory and reported centrally according to predetermined criteria. Results: The qualification procedure was carried out on 15 scanners. All scanners were able to demonstrate the necessary quantitative accuracy, and following modification of image reconstruction where necessary, scanners demonstrated comparable recovery coefficients (RCs) indicating similar performance. The average RC (±1 standard deviation) was 0.56 ± 0.095 for the 13-mm sphere. Reports from 444 of 473 (94%) patients in RAPID and 67 of 73 (92%) patients in RATHL were available for randomisation of therapy. Conclusions: The CTN has enabled consistent quality assured PET results to be obtained from multiple centres in time for clinical decision making. The results of trials will be significantly strengthened by this system. © The Author 2010. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.

AB - Background: Multicentre trials are required to determine how [fluorine-18]-2-fluoro-2-deoxy-D-glucose-positron emission tomography imaging can guide cancer treatment. Consistency in quality control (QC), scan acquisition and reporting is mandatory for high-quality results, which are comparable across sites. Methods: A national positron emission tomography (PET) clinical trials network (CTN) has been set up with a 'core laboratory' to coordinate QC and interpret scans. The CTN is involved in trials in Hodgkin's lymphoma [Randomised Phase III trial to determine the role of FDG-PET Imaging in Clinical Stages IA/IIA Hodgkin's Disease (RAPID) and Randomised Phase III trial to assess response adapted therapy using FDG-PET imaging in patients with newly diagnosed, advanced Hodgkin lymphoma (RATHL)] and diffuse large B-cell lymphoma [Blinded evaluation of prognostic value of FDG-PET after 2 cycles of chemotherapy in diffuse large B-cell Non-Hodgkins Lymphoma, a sub-study of the R-CHOP-21 vs R-CHOP-14 trial (R-CHOP PET substudy)]. Approval to join requires scanner validation and agreement to follow a standard QC protocol. Scans are transferred to the core laboratory and reported centrally according to predetermined criteria. Results: The qualification procedure was carried out on 15 scanners. All scanners were able to demonstrate the necessary quantitative accuracy, and following modification of image reconstruction where necessary, scanners demonstrated comparable recovery coefficients (RCs) indicating similar performance. The average RC (±1 standard deviation) was 0.56 ± 0.095 for the 13-mm sphere. Reports from 444 of 473 (94%) patients in RAPID and 67 of 73 (92%) patients in RATHL were available for randomisation of therapy. Conclusions: The CTN has enabled consistent quality assured PET results to be obtained from multiple centres in time for clinical decision making. The results of trials will be significantly strengthened by this system. © The Author 2010. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.

KW - Clinical trial

KW - Core laboratory

KW - Hodgkin's lymphoma

KW - Non-Hodgkin's lymphoma

KW - Positron emission tomography

KW - Quality control/quality assurance

U2 - 10.1093/annonc/mdq428

DO - 10.1093/annonc/mdq428

M3 - Article

C2 - 20813876

SN - 1569-8041

VL - 22

SP - 739

EP - 745

JO - Annals of Oncology

JF - Annals of Oncology

IS - 3

ER -

Establishment of a UK-wide network to facilitate the acquisition of quality assured FDG-PET data for clinical trials in lymphoma

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this